Related Experiment Video
Updated: May 9, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Structure evaluation coupled with all-atom molecular dynamics and advanced quantum mechanical DFT revealed kaempferol
Shabir Ahmad Ganai1, Sundararaj Rajamanikandan2, Shahid Ahmad Padder1
1Division of Basic Sciences and Humanities, FoH, SKUAST-Kashmir, Shalimar, Srinagar, Jammu and Kashmir 190025, India.
Abstract:
Aberrant histone deacetylase-9 (HDAC9) activity has been recorded in a plethora of malignant tumors, including gastric cancer, hepatocellular carcinoma, and non-small cell lung cancer. Despite the discovery of HDAC9 as an important pharmacological target, the non-availability of its three-dimensional structure has substantially obstructed the process of discovering potent plant-based therapeutics against it. The present study determined the tertiary structure of human HDAC9 and validated its accuracy. Following this, the binding characteristics of diverse flavonoids against HDAC9 were compared using givinostat as a reference molecule. Moreover, the dynamics of the highest affinity flavonoid and HDAC9 were also investigated in the bound state. Furthermore, the energy gap of the defined flavonoid, signifying the reactivity and kinetic stability, was quantified. We employed multiple techniques, including template-steered modeling, molecular docking, all-atom molecular dynamics, and an atomistic quantum mechanical density functional theory in tandem, for comparing the binding strength of 12 flavonoid molecules against HDAC9 using givinostat (an orphan-approved HDAC inhibitor) as the positive control. Following these procedures, it became discernible that all the flavonoid molecules exhibit stronger binding character and interaction status with this epigenetic target than givinostat. Kaempferol, a flavonol, manifested the strongest affinity among the selected flavonoids and interacted with multiple residues of the deacetylase domain of HDAC9. Similar to givinostat, kaempferol exhibited tenable stability in bound form with this acetylation-eraser enzymatic protein. Most importantly, this flavonol demonstrated higher chemical reactivity and, as such, lower kinetic stability than givinostat which is quite important from a pharmacological perspective.
Insights
Researchers determined the 3D structure of histone deacetylase-9 (HDAC9) and found plant-based flavonoids bind more effectively than the drug givinostat. Kaempferol shows the strongest binding and favorable pharmacological properties for potential cancer therapeutics.
Area of Science:
- Biochemistry and Molecular Biology
- Pharmacology and Drug Discovery
- Structural Biology
Background:
- Aberrant histone deacetylase-9 (HDAC9) activity is implicated in various cancers, making it a key pharmacological target.
- The lack of a determined 3D structure for HDAC9 has hindered the development of novel therapeutics, particularly plant-based compounds.
Purpose of the Study:
- To determine and validate the tertiary structure of human HDAC9.
- To compare the binding affinity of various flavonoids against HDAC9, using givinostat as a reference.
- To investigate the binding dynamics, stability, and chemical reactivity of the top-ranked flavonoid with HDAC9.
Main Methods:
- Template-steered modeling and molecular docking were used to predict binding interactions.
- All-atom molecular dynamics simulations assessed the stability of flavonoid-HDAC9 complexes.
- Quantum mechanical density functional theory quantified the energy gap, indicating reactivity and stability.
Main Results:
- All 12 tested flavonoids demonstrated superior binding affinity and interaction profiles compared to givinostat.
- Kaempferol, a flavonol, exhibited the strongest binding affinity, interacting with key residues in the HDAC9 deacetylase domain.
- Kaempferol displayed comparable stability to givinostat in the bound state, along with higher chemical reactivity, suggesting pharmacological potential.
Conclusions:
- The determined 3D structure of HDAC9 facilitates structure-based drug design.
- Flavonoids, particularly kaempferol, represent promising candidates for developing novel HDAC9 inhibitors.
- Kaempferol's favorable binding, stability, and reactivity profile warrants further investigation as a potential anti-cancer therapeutic agent.
